Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Neoplasms 4Ovarian Neoplasms 3Neoplasm Metastasis 3Carcinoma 3Fallopian Tube Neoplasms 2Sarcoma 1Renal Insufficiency 1Melanoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Kidney Neoplasms 1Kidney Diseases 1Congenital Abnormalities 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1Advanced Solid Tumors 1

Interventions

pembrolizumab 11Nivolumab 7Sunitinib 6Cyclophosphamide 6aldesleukin 5Sorafenib 5Everolimus 5temsirolimus 4belzutifan 4atezolizumab 4Ipilimumab 4fludarabine 3cabozantinib 3Interferon-alpha 3Gene Expression Profiling 3Fluorouracil 3Docetaxel 3Cetuximab 3Busulfan 3valspodar 2sargramostim 2perifosine 2pazopanib 2ixabepilone 2entinostat 2ciforadenant 2belinostat 2Thiotepa 2Temozolomide 2Sirolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Kidney Neoplasms × trebananib × Clear all
NCT03239145 2026-03-12

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Dana-Farber Cancer Institute

Phase 1 Completed
62 enrolled 17 charts
DermatologicGastrointestinalGenitourinaryGynecologic

Kidney Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡